Stockscreener 앱 받기
3.25
2.69%
-0.09
시장 영업 전:
3.36
0.11
+3.38%
전일 마감가:
$3.34
열려 있는:
$3.34
하루 거래량:
811.69K
Relative Volume:
0.39
시가총액:
$312.95M
수익:
-
순이익/손실:
$-84.23M
주가수익비율:
-3.5185
EPS:
-0.9237
순현금흐름:
$-77.15M
1주 성능:
-2.69%
1개월 성능:
-2.40%
6개월 성능:
-66.94%
1년 성능:
-16.67%
1일 변동 폭
$3.24
$3.43
1주일 범위
$2.83
$3.44
52주 변동 폭
$1.07
$11.46
Rezolute Inc Stock (RZLT) Company Profile
명칭
Rezolute Inc
전화
650-206-4507
주소
275 SHORELINE DRIVE, SUITE 500, REDWOOD CITY
Compare RZLT vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RZLT
Rezolute Inc
|
3.25 | 321.62M | 0 | -84.23M | -77.15M | -0.9237 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rezolute Inc Stock (RZLT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-25 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2025-12-11 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-12-11 | 다운그레이드 | Craig Hallum | Buy → Hold |
| 2025-12-11 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2024-11-05 | 개시 | Wedbush | Outperform |
| 2024-08-27 | 개시 | Guggenheim | Buy |
| 2024-07-17 | 개시 | BTIG Research | Buy |
| 2024-06-04 | 개시 | Craig Hallum | Buy |
| 2024-04-09 | 개시 | Maxim Group | Buy |
| 2022-08-02 | 재개 | Canaccord Genuity | Buy |
| 2022-06-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-09-08 | 개시 | ROTH Capital | Buy |
| 2021-05-27 | 개시 | Oppenheimer | Outperform |
| 2021-05-25 | 개시 | H.C. Wainwright | Buy |
모두보기
Rezolute Inc 주식(RZLT)의 최신 뉴스
RZLT Stock Price, Quote & Chart | REZOLUTE INC (NASDAQ:RZLT) - ChartMill
Opaleye Management Inc. Increases Stake in Rezolute Inc. - GuruFocus
Balyasny holds 5,048,421 shares of Rezolute (NASDAQ: RZLT), ~5.28% stake - Stock Titan
RZLT Maintains by Maxim Group -- Price Target Raised to $10.00 - GuruFocus
FDA review puts Rezolute's genetic disorder drug path in question - MSN
Maxim Group Maintains Rezolute(RZLT.US) With Buy Rating, Raises Target Price to $10 - Moomoo
Wedbush Maintains Rezolute(RZLT.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Maxim Group Maintains Rezolute(RZLT.US) With Buy Rating, Maintains Target Price $10 - Moomoo
High Growth Tech Stocks in US for May 2026 - simplywall.st
H.C. Wainwright reiterates Buy on Rezolute stock, $5 target - Investing.com UK
H.C. Wainwright reiterates Buy on Rezolute stock, $5 target By Investing.com - Investing.com Nigeria
TradingKey - TradingKey
Rezolute (RZLT) Q3 FY2026 Earnings: EPS Not Disclosed, Revenue N - GuruFocus
RZLT Reports Significant Decrease in Cash Reserves - GuruFocus
Rezolute, Inc. 3Q 2026: Net loss $16.2M, EPS $(0.16) — 10-Q Summary - TradingView
Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update - The Manila Times
Rezolute (NASDAQ: RZLT) details sunRIZE miss and tumor HI Phase 3 - Stock Titan
Rezolute 3Q Loss/Shr 16c >RZLT - Moomoo
Rezolute (NASDAQ: RZLT) Q3 2026 loss narrows with HI efficacy data - Stock Titan
MSN Money - MSN
Rezolute, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026 - marketscreener.com
Opaleye-affiliated holders report 6.3M shares in Rezolute (RZLT) - Stock Titan
Number of shareholders of Rezolute, Inc. – NASDAQ:RZLT - TradingView
Rezolute Inc. to Present Clinical Development Programs at Investor Conferences - geneonline.com
Rezolute to Participate in Upcoming Investor Conferences - The Manila Times
About Us | Oil & Gas JournalRezolute to Participate in Upcoming Investor Conferences - FinancialContent
Rezolute Announces Positive Phase 3 sunRIZE Results for Ersodetug in Congenital Hyperinsulinism, Shows Significant Glycemic Improvements and FDA Progress 1234 - Minichart
Rezolute Shares Expanded Phase 3 sunRIZE Data With FDA - TipRanks
Phase 3 sunRIZE miss but strong CGM gains for Rezolute (NASDAQ: RZLT) - Stock Titan
Rezolute Buy Rating Reiterated as CGM Data Offset Phase 3 Miss; $5 Price Target Maintained - TipRanks
H.C. Wainwright reiterates Rezolute stock rating on CGM data By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Rezolute stock rating on CGM data - Investing.com
Rezolute presents expanded Phase 3 data for hyperinsulinism drug By Investing.com - Investing.com Australia
Rezolute (RZLT) Presents Positive Findings from Phase 3 sunRIZE Study - GuruFocus
Rezolute presents expanded Phase 3 data for hyperinsulinism drug - Investing.com
Rezolute, Inc. Reports Positive Continuous Glucose Monitoring Outcomes for Ersodetug in Phase 3 sunRIZE Study of Congenital Hyperinsulinism - Quiver Quantitative
Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in ... - Caledonian Record
Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting - The Killeen Daily Herald
Rezolute Stock: FDA Fast Track Fuels 2025 Breakout - MSN
Rezolute shares in focus after RA Capital discloses 9.9% stake - MSN
Rezolute Inc (RZLT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.98%
1.33%
자본화:
|
볼륨(24시간):